Empagliflozin-induced Diabetic Ketoacidosis Unmasking a Type 1 Diabetes Diagnosis

Empagliflozin-induced Diabetic Ketoacidosis Unmasking a Type 1 Diabetes Diagnosis

Empagliflozin is a sodium glucose cotransporter-2 inhibitor that inhibits renal glucose reabsorption through an insulin-independent mechanism. This class of drugs is used in the management of type 2 diabetes. A 49-year-old female with type 2 diabetes treated with empagliflozin presented to the emerg...

Full description

Bibliographic Details
Main Authors: Gretchen M. Ray, Chelsea Rodriguez, Samantha M. Schulman, Preeyaporn Sarangarm, Michelle Bardack, Matthew F. Bouchonville
Format: Article
Language:English
Published: eScholarship Publishing, University of California 2019-05-01
Series:Clinical Practice and Cases in Emergency Medicine
Online Access:https://escholarship.org/uc/item/60k8s17c
id doaj-eeeb469a17fb44ba9972226f2828b08c
record_format Article
spelling doaj-eeeb469a17fb44ba9972226f2828b08c2020-11-25T02:09:58ZengeScholarship Publishing, University of CaliforniaClinical Practice and Cases in Emergency Medicine2474-252X2019-05-013210.5811/cpcem.2019.2.41795cpcem-03-140Empagliflozin-induced Diabetic Ketoacidosis Unmasking a Type 1 Diabetes DiagnosisGretchen M. Ray0Chelsea Rodriguez1Samantha M. Schulman2Preeyaporn Sarangarm3Michelle Bardack4Matthew F. Bouchonville5The University of New Mexico College of Pharmacy, Department of Pharmacy Practice and Administrative Sciences, Albuquerque, New MexicoThe University of New Mexico College of Pharmacy, Albuquerque, New MexicoThe University of New Mexico College of Pharmacy, Albuquerque, New MexicoThe University of New Mexico Hospitals, Department of Pharmacy, Albuquerque, New MexicoThe University of New Mexico School of Medicine, Department of Family and Community Medicine, Albuquerque, New MexicoThe University of New Mexico School of Medicine, Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism, Albuquerque, New MexicoEmpagliflozin is a sodium glucose cotransporter-2 inhibitor that inhibits renal glucose reabsorption through an insulin-independent mechanism. This class of drugs is used in the management of type 2 diabetes. A 49-year-old female with type 2 diabetes treated with empagliflozin presented to the emergency department in diabetic ketoacidosis (DKA). This case report details the series of events leading to the diagnosis of drug-induced DKA, which led to a change in the patient’s diagnosis from type 2 diabetes to type 1 diabetes.https://escholarship.org/uc/item/60k8s17c
collection DOAJ
language English
format Article
sources DOAJ
author Gretchen M. Ray
Chelsea Rodriguez
Samantha M. Schulman
Preeyaporn Sarangarm
Michelle Bardack
Matthew F. Bouchonville
spellingShingle Gretchen M. Ray
Chelsea Rodriguez
Samantha M. Schulman
Preeyaporn Sarangarm
Michelle Bardack
Matthew F. Bouchonville
Empagliflozin-induced Diabetic Ketoacidosis Unmasking a Type 1 Diabetes Diagnosis
Clinical Practice and Cases in Emergency Medicine
author_facet Gretchen M. Ray
Chelsea Rodriguez
Samantha M. Schulman
Preeyaporn Sarangarm
Michelle Bardack
Matthew F. Bouchonville
author_sort Gretchen M. Ray
title Empagliflozin-induced Diabetic Ketoacidosis Unmasking a Type 1 Diabetes Diagnosis
title_short Empagliflozin-induced Diabetic Ketoacidosis Unmasking a Type 1 Diabetes Diagnosis
title_full Empagliflozin-induced Diabetic Ketoacidosis Unmasking a Type 1 Diabetes Diagnosis
title_fullStr Empagliflozin-induced Diabetic Ketoacidosis Unmasking a Type 1 Diabetes Diagnosis
title_full_unstemmed Empagliflozin-induced Diabetic Ketoacidosis Unmasking a Type 1 Diabetes Diagnosis
title_sort empagliflozin-induced diabetic ketoacidosis unmasking a type 1 diabetes diagnosis
publisher eScholarship Publishing, University of California
series Clinical Practice and Cases in Emergency Medicine
issn 2474-252X
publishDate 2019-05-01
description Empagliflozin is a sodium glucose cotransporter-2 inhibitor that inhibits renal glucose reabsorption through an insulin-independent mechanism. This class of drugs is used in the management of type 2 diabetes. A 49-year-old female with type 2 diabetes treated with empagliflozin presented to the emergency department in diabetic ketoacidosis (DKA). This case report details the series of events leading to the diagnosis of drug-induced DKA, which led to a change in the patient’s diagnosis from type 2 diabetes to type 1 diabetes.
url https://escholarship.org/uc/item/60k8s17c
work_keys_str_mv AT gretchenmray empagliflozininduceddiabeticketoacidosisunmaskingatype1diabetesdiagnosis
AT chelsearodriguez empagliflozininduceddiabeticketoacidosisunmaskingatype1diabetesdiagnosis
AT samanthamschulman empagliflozininduceddiabeticketoacidosisunmaskingatype1diabetesdiagnosis
AT preeyapornsarangarm empagliflozininduceddiabeticketoacidosisunmaskingatype1diabetesdiagnosis
AT michellebardack empagliflozininduceddiabeticketoacidosisunmaskingatype1diabetesdiagnosis
AT matthewfbouchonville empagliflozininduceddiabeticketoacidosisunmaskingatype1diabetesdiagnosis
_version_ 1724921467683995648

Similar Items